Takeda Pharmaceutical Co.: Hold Rating Amid Mixed Q3 Results, Upward Guidance Revision, and Strategic Moves
Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...
Takeda signals 2025 growth with raised guidance, JPY 100B buyback, and new leadership transition
Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Management View Christophe Weber, CEO, announced his retirement ...
BioSpace15h
Takeda Drops Epilepsy Drug, Names New CEO Amid Q3 Earnings
Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...
Takeda Pharmaceutical Company Limited (TAK) Q3 2025 Earnings Call Transcript
Takeda Pharmaceutical Company Limited ( NYSE: TAK) Q3 2025 Results Conference Call January 30, 2025 5:30 AM ET Christopher O’Reilly - Head, Investor Relations Christophe Weber - President and Chief ...
Drugmaker Takeda's CEO Weber to step down, raises profit forecast
Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...
Takeda gains after FY24 guidance raise, CEO transition
ADRs traded higher in the premarket on Thursday after the Japanese drugmaker raised its full-year outlook with its Q3 FY24 results and named Julie Kim, head of its U.S. business, as the company’s next ...